A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
PRINCETON, N.J., March 24, 2020 -- Origin, Inc., a Phase III clinical-stage biotechnology company, today announced that it has filed a provisional U.S. patent application to enhance the ability of its plasma-generated nitric oxide (NO) antimicrobial and antiviral...
PRINCETON, New Jersey, Oct. 28, 2019 -- Origin, Inc., a Phase III clinical-stage biotechnology company, today announced that it had applied to NMPA (formerly CFDA) for classification of its plasma-generated nitric oxide device for the purposes of conducting clinical...
PRINCETON, N.J., April 18, 2018 -- Origin, Inc., a Phase IIb clinical-stage biotechnology company, today announced that the US Food and Drug Administration has approved its request to conclude patient recruitment in the "GENESIS" dose-ranging (Phase IIb) trial of...